European Journal of Preventive Cardiology · 2021 · 30 citations · 60 references
Heart FailureStructural Heart DiseaseCardiovascular DiseaseClinical BoundariesPreserved Ejection FractionCardiologyCardiac CareMedicineHfpef Epidemiological BoundariesAtherosclerosisDiastolic FunctionEmergency Medicine
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent and is associated with relevant morbidity and mortality. However, an evidence-based treatment is still absent. The heterogeneous definitions, differences in aetiology/pathophysiology, and diagnostic challenges of HFpEF made it difficult to define its epidemiological landmarks so far. Several large registries and observational studies have recently disclosed an increasing incidence/prevalence, as well as its prognostic significance. An accurate definition of HFpEF epidemiological boundaries and phenotypes is mandatory to develop novel effective and rational therapeutic approaches.
60
PubMed · 2021 · 19.5K citations
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 4.8K citations · Full text
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler et al. · New England Journal of Medicine · 2020 · 4.7K citations · Full text